Loading clinical trials...
Loading clinical trials...
Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Conditions
Interventions
PZ01 CAR-T cells
Locations
1
China
Department of Hematology, Navy General Hospital of PLA
Beijing, Beijing Municipality, China
Start Date
October 1, 2017
Primary Completion Date
September 1, 2020
Completion Date
November 1, 2020
Last Updated
September 15, 2017
NCT05139017
NCT06026319
NCT01804686
NCT05442515
NCT05755087
NCT06045247
Lead Sponsor
Pinze Lifetechnology Co. Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions